| 1977 |
Nielsen HV, Weeth R, Eriksen E. Lesions in belted car riders from oblique and lateral impacts. In: Proceedings of the 1977 International IRCOBI Conference on the Biomechanics of Impact. September 7-9, 1977; Berlin, Germany.180-193. |
2 |
2 |
| 1985 |
Eriksen EF, Mosekilde L, Melsen F. Trabecular bone resorption depth decreases with age: differences between normal males and females. Bone. 1985;6(3):141-146. |
20 |
17 |
| 1992 |
Steiniche T, Eriksen EF, Kudsk H, Mosekilde L, Melsen F. Reconstruction of the formative site in trabecular bone by a new, quick, and easy method. Bone. 1992;13(2):147-152. |
8 |
5 |
| 1993 |
Brockstedt H, Kassem M, Eriksen EF, Mosekilde L, Melsen F. Age- and sex-related changes in iliac cortical bone mass and remodeling. Bone. July–August 1993;14(4):681-691. |
31 |
30 |
| 2002 |
Eriksen E, Melsen F, Sod E, Barton I, Chines A. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone. November 2002;31(5):620-625. |
27 |
23 |
| 2017 |
Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guañabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC. Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone. December 2017;105:11-17. |
23 |
22 |
| 2020 |
Stunes AK, Erben RG, Schüler C, Eriksen EF, Tice M, Vashishth D, Syversen U, Mosti MP. Skeletal effects of plyometric exercise and metformin in ovariectomized rats. Bone. March 2020;132:115193. |
1 |
0 |
| 2020 |
Rubin KH, Möller S, Choudhury A, Zorina O, Kalsekar S, Eriksen EF, Andersen M, Abrahamsen B. Cardiovascular and skeletal safety of zoledronic acid in osteoporosis observational, matched cohort study using Danish and Swedish health registries. Bone. May 2020;134:115296. |
3 |
3 |
| 2020 |
Reid IR, Green JR, Lyles KW, Reid DM, Trechsel U, Hosking DJ, Black DM, Cummings SR, Russell RGG, Eriksen EF. Zoledronate. Bone. August 2020;137:115390. |
4 |
3 |
| 2021 |
Eriksen EF, Shabestari M, Ghouri A, Conaghan PG. Bisphosphonates as a treatment modality in osteoarthritis. Bone. February 2021;143:115352. |
0 |
0 |
| 2022 |
Paschalis EP, Gamsjaeger S, Klaushofer K, Shane E, Cohen A, Stepan J, Pavo I, Eriksen EF, Taylor KA, Dempster DW. Treatment of postmenopausal osteoporosis patients with teriparatide for 24 months reverts forming bone quality indices to premenopausal healthy control values. Bone. September 2022;162:116478. |
0 |
0 |
| 2016 |
Diez-Perez A, Bouxsein M, Eriksen E, Khosla S, Nyman J, Papapoulos S, Tang S. Technical note: recommendations for a standard procedure to assess cortical bone at the tissue-level in vivo using impact microindentation. Bone Rep. December 2016;5:181-185. |
15 |
5 |
| 1986 |
Eriksen EF. Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodeling sequence in normals and in metabolic bone disease. Endocr Rev. November 1986;7(4):379-408. |
62 |
54 |
| 1999 |
Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH III, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD; Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. October 13, 1999;282(14):1344-1352. |
106 |
89 |
| 1990 |
Eriksen EF, Hodgson SF, Eastell R, Cedel SL, O'Fallon WM, Riggs BL. Cancellous bone remodeling in type I (postmenopausal) osteoporosis: quantitative assessment of rates of formation, resorption, and bone loss at tissue and cellular levels. J Bone Miner Res. April 1990;5(4):311-319. |
43 |
36 |
| 2001 |
Hauge EM, Qvesel D, Eriksen EF, Mosekilde L, Melsen F. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res. September 2001;16(9):1575-1582. |
23 |
19 |
| 2003 |
Paschalis EP, Boskey AL, Kassem M, Eriksen EF. Effect of hormone replacement therapy on bone quality in early postmenopausal women. J Bone Miner Res. June 2003;18(6):955-959. |
15 |
6 |
| 2003 |
Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone (1–34) [teriparatide] improves both cortical and cancellous bone structure. J Bone Miner Res. November 2003;18(11):1932-1941. |
45 |
42 |
| 2006 |
Ma YL, Zeng Q, Donley DW, Ste‐Marie L, Gallagher JC, Dalsky GP, Marcus R, Eriksen EF. Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF‐II immunoreactivity in postmenopausal women with osteoporosis. J Bone Miner Res. June 2006;21(6):855-864. |
30 |
28 |
| 2008 |
Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, García-Hernandez PA, Supronik J, Lewiecki EM, Ochoa L, Miller P, Hu H, Mesenbrink P, Hartl F, Gasser J, Eriksen EF. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res. January 2008;23(1):6-16. |
18 |
13 |
| 2011 |
Gamsjaeger S, Buchinger B, Zwettler E, Recker R, Black D, Gasser JA, Eriksen EF, Klaushofer K, Paschalis EP. Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly zoledronic acid. J Bone Miner Res. January 2011;26(1):12-18. |
21 |
16 |
| 2016 |
Paschalis EP, Fratzl P, Gamsjaeger S, Hassler N, Brozek W, Eriksen EF, Rauch F, Glorieux FH, Shane E, Dempster D, Cohen A, Recker R, Klaushofer K. Aging versus postmenopausal osteoporosis: bone composition and maturation kinetics at actively-forming trabecular surfaces of female subjects aged 1 to 84 years. J Bone Miner Res. February 2016;31(2):347-357. |
16 |
8 |
| 2022 |
Eriksen EF, Chapurlat R, Boyce RW, Shi Y, Brown JP, Horlait S, Betah D, Libanati C, Chavassieux P. Modeling-based bone formation after 2 months of romosozumab treatment: results from the FRAME clinical trial. J Bone Miner Res. January 2022;37(1):36-40. |
1 |
1 |
| 2023 |
Diez-Perez A, Cordomí CT, Eriksen EF, Pasco JA. Increased BMSi association with risk of incident osteoporotic fractures. J Bone Miner Res. October 2023;38(10):1541-1542. |
0 |
0 |
| 1984 |
Eriksen EF, Melsen F, Mosekilde L. Reconstruction of the resorptive site in iliac trabecular bone: a kinetic model for bone resorption in 20 normal individuals. Metab Bone Dis Rel Res. 1984;5(5):235-242. |
31 |
27 |
| 2001 |
Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster J-Y, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mellström D, Oefjord ES, Marcinowska-Suchowierska E, Salmi J, Mulder H, Halse J, Sawicki AZ, Mitlak BH. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. NEJM. May 10, 2001;344(19):1434-1441. |
158 |
146 |
| 2007 |
Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR; HORIZON Pivotal Fracture Trial. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. NEJM. May 3, 2007;356(18):1809-1822. |
90 |
66 |
| 2007 |
Lyles KW, Colón-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S; HORIZON Recurrent Fracture Trial. Zoledronic acid and clinical fractures and mortality after hip fracture. NEJM. November 1, 2007;357(18):1799-1809. |
82 |
79 |
| 2020 |
Borgen TT, Bjørnerem Å, Solberg LB, Andreasen C, Brunborg C, Stenbro M-B, Hübschle LM, Figved W, Apalset EM, Gjertsen J-E, Basso T, Lund I, Hansen AK, Stutzer J-M, Dahl C, Nordsletten L, Frihagen F, Eriksen EF. Determinants of trabecular bone score and prevalent vertebral fractures in women with fragility fractures: a cross-sectional sub-study of NoFRACT. Osteoporos Int. March 2020;31(3):505-514. |
0 |
0 |
| 2010 |
Eriksen EF. Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord. December 2010;11(4):219-227. |
53 |
53 |